Skip to content

Study · Case report or series · n = 2 · 2021

3 results

Liraglutide with Lifestyle Intervention in Adolescents with Overweight/Obesity, Nonalcoholic Fatty Liver Disease, and Type II Diabetes Mellitus.

Kohut T, Panganiban J

JPGN reports8 Nov 2021Cited by 6 (Europe PMC)

PMID37206449 (opens in a new tab)PMCIDPMC10191552 (opens in a new tab)DOI10.1097/pg9.0000000000000141 (opens in a new tab)PepBankPUB-37206449
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In two adolescent females with type 2 diabetes and biopsy-proven NASH, liraglutide treatment was associated with weight loss.

    In plain wordsIn two teenage girls with diabetes and fatty liver disease, liraglutide treatment was linked to weight loss.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss
    Study

    n = 2

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We report two adolescent females with T2DM and biopsy proven nonalcoholic steatohepatitis (NASH) refractory to lifestyle intervention who were safety treated with liraglutide with associated weight loss and liver enzyme improvement.
  2. 02HumanCase report or seriesEfficacy outcome

    In two adolescent females with type 2 diabetes and biopsy-proven NASH, liraglutide treatment was associated with improvement in liver enzymes.

    In plain wordsIn two teenage girls with diabetes and fatty liver disease, liraglutide treatment was linked to better liver enzyme results.

    Peptide
    Liraglutide
    Outcome
    DecreaseLiver enzymes
    Study

    n = 2

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We report two adolescent females with T2DM and biopsy proven nonalcoholic steatohepatitis (NASH) refractory to lifestyle intervention who were safety treated with liraglutide with associated weight loss and liver enzyme improvement.
  3. 03HumanCase report or seriesSafety outcome

    In two adolescent females with type 2 diabetes and biopsy-proven NASH, the authors report that liraglutide treatment was safe.

    In plain wordsIn two teenage girls with diabetes and fatty liver disease, the authors report liraglutide treatment was safe.

    Peptide
    Liraglutide
    Outcome
    Not applicableSafety of treatment
    Study

    n = 2

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We report two adolescent females with T2DM and biopsy proven nonalcoholic steatohepatitis (NASH) refractory to lifestyle intervention who were safety treated with liraglutide with associated weight loss and liver enzyme improvement.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.